- Home
- ANEB vs TCRX Comparison
ANEB vs TCRX Comparison
Compare ANEB & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- TCRX
- Stock Information
- Founded
- ANEB 2020
- TCRX 2018
- Country
- ANEB United States
- TCRX United States
- Employees
- ANEB N/A
- TCRX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- TCRX Health Care
- Exchange
- ANEB Nasdaq
- TCRX Nasdaq
- Market Cap
- ANEB 90.4M
- TCRX 91.7M
- IPO Year
- ANEB 2021
- TCRX 2021
- Fundamental
- Price
- ANEB $2.45
- TCRX $1.73
- Analyst Decision
- ANEB Buy
- TCRX Strong Buy
- Analyst Count
- ANEB 2
- TCRX 5
- Target Price
- ANEB $8.00
- TCRX $9.40
- AVG Volume (30 Days)
- ANEB 127.6K
- TCRX 218.2K
- Earning Date
- ANEB 11-12-2025
- TCRX 11-11-2025
- Dividend Yield
- ANEB N/A
- TCRX N/A
- EPS Growth
- ANEB N/A
- TCRX N/A
- EPS
- ANEB N/A
- TCRX N/A
- Revenue
- ANEB N/A
- TCRX $6,961,000.00
- Revenue This Year
- ANEB N/A
- TCRX $255.18
- Revenue Next Year
- ANEB N/A
- TCRX N/A
- P/E Ratio
- ANEB N/A
- TCRX N/A
- Revenue Growth
- ANEB N/A
- TCRX N/A
- 52 Week Low
- ANEB $0.80
- TCRX $1.02
- 52 Week High
- ANEB $3.42
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- ANEB 52.56
- TCRX 44.78
- Support Level
- ANEB $2.33
- TCRX $1.65
- Resistance Level
- ANEB $2.58
- TCRX $1.96
- Average True Range (ATR)
- ANEB 0.16
- TCRX 0.10
- MACD
- ANEB -0.00
- TCRX -0.02
- Stochastic Oscillator
- ANEB 72.34
- TCRX 25.81
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.